Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514447 | 0.79 | MAPT (0.56) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL5381308 | 0.79 | MAPT (0.56) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL5386051 | 0.79 | GP6 (0.48) | ALDH1A1MAPTCHEK1 | |
| SCHEMBL5372659 | 0.79 | AURKA (0.58) | ALDH1A1MAPTCHEK1AURKA | |
| SCHEMBL5374376 | 0.79 | MAPT (0.55) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL5374202 | 0.78 | AURKA (0.52) | MAPTMEN1POLBKMT2AUSP2 | |
| SCHEMBL7533484 | 0.77 | MAP2K4 (0.59) | AURKA | |
| SCHEMBL5375007 | 0.77 | MAPT (0.51) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL5383308 | 0.76 | KMT2A (0.56) | MAPTMEN1POLBKMT2AUSP2 | |
| SCHEMBL5379422 | 0.76 | XDH (0.67) | ALDH1A1MAPTPFKFB3PFKFB4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | ALDH1A1 2864/4885MAPT 1000/4885PFKFB3 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.